Fairfield Financial Advisors LTD Sells 18,909 Shares of Novo Nordisk A/S $NVO

Fairfield Financial Advisors LTD cut its stake in Novo Nordisk A/S (NYSE:NVO) by 62.3% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,449 shares of the company’s stock after selling 18,909 shares during the quarter. Fairfield Financial Advisors LTD’s holdings in Novo Nordisk A/S were worth $635,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Revolve Wealth Partners LLC grew its position in Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the period. AQR Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 21.0% in the 1st quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after buying an additional 10,758 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Novo Nordisk A/S in the first quarter worth $3,157,000. SCS Capital Management LLC bought a new stake in shares of Novo Nordisk A/S in the first quarter worth $503,000. Finally, Focus Partners Wealth increased its position in Novo Nordisk A/S by 17.6% during the first quarter. Focus Partners Wealth now owns 453,434 shares of the company’s stock valued at $31,489,000 after acquiring an additional 67,853 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Amazon Pharmacy began offering Novo Nordisk’s new Wegovy pill through insurance plans and a cash-pay option, expanding U.S. distribution and making the first-ever oral GLP‑1 from Novo more accessible to patients — a direct demand and revenue catalyst. Amazon Pharmacy offers Novo Nordisk’s Wegovy pill
• Positive Sentiment: Major retail pharmacy availability reported by CNBC/MSN increases distribution visibility and could shorten the time to volume adoption for the Wegovy pill, supporting revenue upside versus slower clinic-based rollouts. Amazon Pharmacy starts offering Novo Nordisk’s Wegovy weight-loss pill
• Positive Sentiment: Investor research pieces flag Novo as a top pick for 2026 and highlight the FDA‑approved Wegovy pill as a growth catalyst; analysts note robust margins and free cash flow potential (but also cite pricing and competition risks). This supportive analyst tone can lift sentiment and trading interest. Novo Nordisk: A Pill For Growth
• Neutral Sentiment: The JPMorgan Healthcare Conference will put pharma pipeline updates and potential M&A back in focus; Novo may benefit from heightened investor attention but concrete impacts depend on announcements made at the event. Healthy Returns: What to expect from pharma at the JPM conference
• Neutral Sentiment: Marketing and PR activities — e.g., a public conversation on weight stigma at a major NYC commuter hub — help brand and patient engagement but are unlikely to move near-term revenue materially. Novo Nordisk conducts a new conversation on weight stigma at major NYC commuter hub
• Neutral Sentiment: Recent price commentary (Zacks note on a modest prior-day gain) reflects momentum but is informational rather than a fundamental driver. Novo Nordisk (NVO) Surpasses Market Returns

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Zacks Research cut shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 3rd. BMO Capital Markets reiterated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 23rd. Finally, Jefferies Financial Group initiated coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $56.21.

Novo Nordisk A/S Price Performance

NYSE NVO opened at $58.85 on Friday. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 12 month low of $43.08 and a 12 month high of $93.80. The stock has a market cap of $262.78 billion, a price-to-earnings ratio of 17.11 and a beta of 0.66. The company’s 50 day moving average is $49.65 and its two-hundred day moving average is $55.40.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.